IDEAYA Biosciences, Inc.
IDYA
$17.45
-$0.90-4.91%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 78.48% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 78.48% | -- | -- | -- |
| Cost of Revenue | 65.60% | 261.58% | 69.59% | 86.90% | 53.65% |
| Gross Profit | -65.60% | -282.18% | -122.70% | -112.74% | -114.25% |
| SG&A Expenses | 64.43% | 54.97% | 23.88% | 46.91% | 30.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 65.41% | 229.71% | 60.94% | 79.09% | 49.35% |
| Operating Income | -65.41% | -243.87% | -99.53% | -98.50% | -94.14% |
| Income Before Tax | -82.40% | -283.78% | -88.85% | -88.97% | -67.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.40% | -283.78% | -88.85% | -88.97% | -67.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.40% | -283.78% | -88.85% | -88.97% | -67.39% |
| EBIT | -65.41% | -243.87% | -99.53% | -98.50% | -94.14% |
| EBITDA | -66.24% | -247.72% | -101.65% | -100.39% | -96.18% |
| EPS Basic | -55.04% | -186.70% | -31.49% | -36.33% | -7.82% |
| Normalized Basic EPS | -55.06% | -152.05% | -31.49% | -36.35% | -7.79% |
| EPS Diluted | -55.04% | -186.70% | -31.49% | -36.33% | -7.82% |
| Normalized Diluted EPS | -55.06% | -152.05% | -31.49% | -36.35% | -7.79% |
| Average Basic Shares Outstanding | 17.64% | 33.86% | 43.65% | 38.60% | 55.28% |
| Average Diluted Shares Outstanding | 17.64% | 33.86% | 43.65% | 38.60% | 55.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |